Opicapone - BIAL
Alternative Names: [14C]-BIA 9-1067; BIA-91067; Ongentys; ONO-2370Latest Information Update: 15 May 2026
At a glance
- Originator BIAL
- Developer BIAL; Neurocrine Biosciences; Ono Pharmaceutical
- Class Antiparkinsonians; Nitrobenzenes; Oxadiazoles; Oxides; Pyridines
- Mechanism of Action Catechol O-methyltransferase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Parkinson's disease
Most Recent Events
- 31 Dec 2025 Amneal Pharmaceuticals exercises a licensing agreement with BIAL to market and distribute opicapone
- 05 Apr 2025 Efficacy data from the phase III EPSILON trial in Parkinson’s disease presented at the 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)
- 26 Jan 2024 BIAL completes a phase III EPSILON trial for Parkinson's disease (Adjunctive treatment) in Czech Republic, Bularia, France, Belgium, Italy and Portugal (EudraCT2020-005011-52)